Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Ousia Pharma ApS
APS
Active
CVR 43055909
Ole Maaløes Vej 3, 2200
København N
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2022 · 4 years old
8 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Ousia Pharma ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (3)
CC
Christoffer Clemmensen
Management
Management
2022
AB
Anders Bue Klein
Management
Management
2022
JO
Jonas Odgaard Petersen
Management
Management
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (4)
ME
Margareta Elisabeth Björk
Board of Directors
Board of Directors
2025
IR
Ian Rodney Laquian
Chairman
Chairman
2023
OS
Otello Stampacchia
Board of Directors
Board of Directors
2025
MN
Menelas Nicolas Pangalos
Board of Directors
Board of Directors
2025
Former (3)
MP
Morten Peltola Toft
Board of Directors
Board of Directors
2023 – 2025
JR
Jeppe Ragnar Andersen
Board of Directors
Board of Directors
2023 – 2025
MS
Mikael Søndergaard Thomsen
Board of Directors
Board of Directors
2023 – 2025
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Omega Fund VIII, L.P
Individual
15–19.99%
15–19.99%
2025
Nordic Alchemy Holding ApS
Company
15–19.99%
15–19.99%
2025
Klein Science Holding ApS
Company
15–19.99%
15–19.99%
2025
Science Studio Holding ApS
Company
15–19.99%
15–19.99%
2025
BII Holdings A/S
Company
10–14.99%
10–14.99%
2025
BioInnovation Institute Fonden
Company
10–14.99%
10–14.99%
2025
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Ousia Pharma ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network